NASDAQ · CLYM
Healthcare · Biotechnology
$11.00
Up+$0.14 (+1.29%)
Updated Oct 12, 2026, 9:04 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CLYM
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
CLYM closed at $11.00 after 20 trading sessions, down 24.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $10.81 | $11.30 | $10.75 | $11.00 | 638.14K |
| Oct 8, 2026 | $10.55 | $11.00 | $10.27 | $10.86 | 1.15M |
| Oct 7, 2026 | $10.43 | $10.945 | $10.34 | $10.71 | 755.81K |
| Oct 6, 2026 | $11.12 | $11.25 | $10.64 | $10.68 | 954.53K |
| Oct 5, 2026 | $10.94 | $11.20 | $10.70 | $11.05 | 1.21M |
| Oct 2, 2026 | $11.29 | $11.29 | $10.73 | $10.94 | 1.58M |
| Oct 1, 2026 | $11.39 | $11.67 | $11.03 | $11.07 | 953.16K |
| Sep 30, 2026 | $11.69 | $11.93 | $11.32 | $11.47 | 1.41M |
| Sep 29, 2026 | $11.79 | $11.805 | $11.31 | $11.50 | 1.14M |
| Sep 28, 2026 | $11.57 | $11.93 | $11.3898 | $11.74 | 811.3K |
| Sep 25, 2026 | $11.89 | $11.92 | $11.53 | $11.66 | 1.53M |
| Sep 24, 2026 | $12.35 | $12.42 | $11.38 | $11.89 | 1.87M |
| Sep 23, 2026 | $14.29 | $14.39 | $12.06 | $12.52 | 2.14M |
| Sep 22, 2026 | $13.75 | $14.29 | $13.63 | $14.21 | 930.13K |
| Sep 21, 2026 | $14.13 | $14.23 | $13.545 | $13.64 | 1.22M |
| Sep 18, 2026 | $14.15 | $14.44 | $13.92 | $14.05 | 4.05M |
| Sep 17, 2026 | $14.49 | $14.655 | $13.765 | $14.06 | 1.4M |
| Sep 16, 2026 | $14.00 | $14.55 | $13.865 | $14.11 | 2.62M |
| Sep 15, 2026 | $14.705 | $14.705 | $13.375 | $13.91 | 1.55M |
| Sep 14, 2026 | $14.49 | $14.96 | $14.30 | $14.56 | 1.09M |
The latest Smart Investors Daily articles mentioning CLYM.
Company
Market Activity
Research & News
CLYM research
Company profile and research snapshot.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | Oppenheimer | Outperform | — |
| Sep 8, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 4, 2026 | B. Riley Securities | Buy | — |
| Sep 3, 2026 | Baird | Outperform | — |
| Sep 3, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Oct 7, 2026
Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug. Click for more on the bullish thesis for CLYM.
Yahoo · Oct 2, 2026
Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation Presentations on CLYM116 and budoprutug programs highlight advancements across the portfolio WELLESLEY HILLS, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and b
Benzinga · Oct 2, 2026
Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and
Yahoo · Oct 1, 2026
Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CLYM.
